Biomarker for Peritoneal Ultrafiltration Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-10-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine the peritoneal tissue, serum and dialysate proteins of peritoneal dialysis (PD) patients with different types of peritoneal solute transport by differential proteomics techniques.

This study will be performed to identify the molecular difference between different types of peritoneal solute transport and explore biomarker for early detection as well as early intervention of peritoneal ultrafiltration failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease

NCT06962891

Chronic Kidney Disease(CKD) Progression, Disease

ACTIVE_NOT_RECRUITING

Uremic Toxins and Outcomes in Chronic Kidney Disease

NCT03711617

Chronic Kidney Diseases

RECRUITING

Cohort Follow-up: Progression and Consequences of Chronic Kidney Disease.

NCT04070885

Chronic Renal Diseases Renal Function Disorder

COMPLETED

Establish and Apply the Evaluation System of Ultrasonic Integrated Technology for Prevention and Treatment of Acute Kidney Injury

NCT02347930

Acute Kidney Injury

COMPLETED

Peritoneal Ultrafiltration to Treat Congestive Heart Failure

NCT02829450

Chronic Kidney Disease Congestive Heart Failure

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ultrafiltration failure (UFF) is an important cause of technical failure in PD patients. It may develop over time and is, therefore, especially important in longterm PD. However, the study on UFF is very limited so far, there are still lack of biomarker for early detection and intervention of UFF.

Proteomics uses a rapidly evolving group of technologies to identify, quantify, and characterize a global set of proteins. It is characterized by high-throughput, high specificity and high-sensitivity. Therefore, proteomics has become a major focus of recent medical research.

This study will examine the peritoneal tissue, serum and dialysate proteins of continuous ambulatory peritoneal dialysis (CAPD) patients with different types of peritoneal solute transport by differential proteomics techniques. Correlation analysis will be used for the relationship between clinical data and the differential proteins, as well as verification of the differential proteins in the peritoneal tissue, serum and dialysate of patients with UFF. This study will be performed to identify the molecular difference between different types of peritoneal solute transport and explore biomarker for early detection as well as early intervention of peritoneal ultrafiltration failure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Continuous Ambulatory Peritoneal Dialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Continuous ambulatory peritoneal dialysis patients whose primary disease is chronic glomerulonephritis, The range of age is 20 to 65 year old.
* serum albumin level ≥ 35 g/L.
* Residual GFR ≥ 2 ml/min/1.73 m2.
* 500 ml/d ≤ urine output ≤ 1000 ml/d.
* Subjects who agree to participate in the study and sign the informed consent.

Exclusion Criteria

* Patients who are secondary nephropathy.
* Patients with congestive heart failure, angina, myocardial infarction, severe valvular heart disease, malignant hypertension, hypertensive encephalopathy or cerebrovascular accident.
* Patients with chronic liver disease, dyscrasia, psychiatric disorder, alcohol or drug abuse.

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No